HOME > BUSINESS
BUSINESS
- Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec
June 16, 2025
- Japan Vaccine Market to Reach 297 Billion Yen in FY2025: Fuji Keizai
June 13, 2025
- SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
June 13, 2025
- Nippon Chemiphar to Launch Amaryl AGs on June 20
June 13, 2025
- Takeda’s Livmarli, HyQvia Now Available in Japan
June 13, 2025
- Boehringer Files Nerandomilast for Pulmonary Fibrosis in Japan
June 13, 2025
- Pfizer Pushes Back Champix Re-Supply Plan on Regulatory Delay
June 12, 2025
- AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
- Prashant Nikam to Take Over Helm of MSD Japan
June 12, 2025
- Takeda Seeks Japan Nod for Vonvendi Use in Patients Under 18
June 11, 2025
- Enhertu Enters PIII for 1st-Line Endometrial Cancer Use: Daiichi
June 11, 2025
- Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
- Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
- SSP Files for OTC Switch of Tadalafil in Japan
June 10, 2025
- Nipro, Samsung Bioepis Tie Up on Biosimilar Business in Japan
June 10, 2025
- Sawai Follows Fuso to Challenge Remitch Patent Ruling
June 10, 2025
- Otsuka’s Sibeprenlimab Scores Positive Results in PIII: Interim Analysis
June 9, 2025
- Sumitomo Divests Canadian Business to Knight
June 9, 2025
- BMS Files Label Expansion of Sotyktu for Psoriatic Arthritis in Japan
June 9, 2025
- Tivdak Offers Valuable New Option as 2nd-Line Cervical Cancer Therapy: Oncologist
June 9, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
